Get the Stockscreener App
49.22
3.26%
1.555
After Hours:
49.35
0.13
+0.26%
Monopar Therapeutics Inc stock is traded at $49.22, with a volume of 22,332.
It is up +3.26% in the last 24 hours and up +37.10% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$47.66
Open:
$47.89
24h Volume:
22,332
Relative Volume:
0.53
Market Cap:
$303.69M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-21.40
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+11.33%
1M Performance:
+37.10%
6M Performance:
+59.29%
1Y Performance:
+1,146%
1-Day Range:
$45.52
$49.81
1-Week Range:
$41.12
$49.81
52-Week Range:
$3.33
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
49.22 | 264.69M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
What MACD signals say about Monopar Therapeutics Inc.Gap Down & Risk Adjusted Buy and Sell Alerts - Newser
will monopar therapeutics inc. bounce back from current supportMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Analyzing net buyer seller activity in Monopar Therapeutics Inc.Portfolio Risk Summary & Pattern Based Trade Signal System - Newser
Detecting support and resistance levels for Monopar Therapeutics Inc.Gold Moves & Detailed Earnings Play Alerts - Newser
Evaluating Monopar Therapeutics Inc. with trendline analysisBond Market & Stepwise Entry/Exit Trade Alerts - Newser
Using data models to predict Monopar Therapeutics Inc. stock movementJuly 2025 PostEarnings & Real-Time Volume Analysis - Newser
Momentum divergence signals in Monopar Therapeutics Inc. chartJuly 2025 Review & Free Technical Pattern Based Buy Signals - Newser
Is now a turning point for Monopar Therapeutics Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
Can machine learning forecast Monopar Therapeutics Inc. recovery2025 Top Gainers & Step-by-Step Trade Execution Guides - Newser
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
BTIG Research Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Is Monopar Therapeutics Inc. reversing from oversold territoryEarnings Performance Report & Weekly Setup with High ROI Potential - Newser
Detecting price anomalies in Monopar Therapeutics Inc. with AIJuly 2025 Review & Entry Point Confirmation Signals - Newser
Has Monopar Therapeutics Inc. found a price floorTrade Volume Summary & Short-Term High Return Ideas - Newser
Should you hold or exit Monopar Therapeutics Inc. now2025 Investor Takeaways & Daily Price Action Insights - Newser
Why Monopar Therapeutics Inc. is moving todayTrade Entry Summary & Verified Short-Term Plans - Newser
How to build a custom watchlist for Monopar Therapeutics Inc.2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
statistical indicators supporting monopar therapeutics inc.’s strengthEarnings Growth Summary & Verified Momentum Watchlists - Newser
How moving averages guide Monopar Therapeutics Inc. trading2025 Market WrapUp & Daily Price Action Insights - Newser
Does Monopar Therapeutics Inc. fit your quant trading modelQuarterly Market Summary & Expert Approved Momentum Ideas - Newser
BTIG initiates Monopar Therapeutics stock with Buy rating on Wilson’s Disease therapy - Investing.com Canada
BTIG Initiates Monopar Therapeutics at Buy With $87 Price Target - MarketScreener
Will Monopar Therapeutics Inc. see short term momentumJuly 2025 Retail & Weekly Momentum Picks - Newser
Real time pattern detection on Monopar Therapeutics Inc. stockJuly 2025 Summary & Accurate Technical Buy Alerts - Newser
OMERS ADMINISTRATION Corp Makes New Investment in Monopar Therapeutics Inc. $MNPR - MarketBeat
Monopar Therapeutics Inc. At Decision Level — Rebound or ResistanceMarket Trend Review & Fast Moving Market Watchlists - beatles.ru
Using Bollinger Bands to evaluate Monopar Therapeutics Inc.Market Movers & AI Based Trade Execution Alerts - Newser
Short interest data insights for Monopar Therapeutics Inc.2025 Historical Comparison & Weekly Top Gainers Trade List - Newser
Is Monopar Therapeutics Inc. meeting your algorithmic filter criteriaTrade Entry Summary & Weekly Breakout Stock Alerts - Newser
Monopar Therapeutics Inc. Approaches Psychological Resistance Level2025 Short Interest & Stock Timing and Entry Methods - beatles.ru
Is Monopar Therapeutics Inc. impacted by rising ratesDollar Strength & Target Return Focused Picks - beatles.ru
Oppenheimer Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):